problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201258225-28problendo-4591Research ArticleСтатьиArticlesВлияние метформина на продукцию провоспалительных цитокинов и инсулинорезистентность (NF-kB-сигнальный путь)The action of metformin on the production of pro-inflammatory cytokines and insulin resistance (NF-kB signal pathway)LavrenkoA V-KutsenkoN L-KutsenkoL A-MamontovaT V-KaĭdashevI Pkaidashev@yandex.ru201215042012582ТОМ 58, №2 (2012)2528Copyright © Lavrenko A.V., Kutsenko N.L., Kutsenko L.A., Mamontova T.V., Kaĭdashev I.P., 20122012Lavrenko A.V., Kutsenko N.L., Kutsenko L.A., Mamontova T.V., Kaĭdashev I.P.Lavrenko A.V., Kutsenko N.L., Kutsenko L.A., Mamontova T.V., Kaĭdashev I.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4591

Цель данного исследования - оценка роли NF-kB-сигнального пути в реализации противовоспалительного и инсулиносенситайзерного действия метформина у больных ишемической болезнью сердца (ИБС) на фоне метаболического синдрома (МС). Включение ежемесячного курса метформина в комплексную терапию ИБС снижало продукцию провоспалительных цитокинов ИЛ-1Β, ИЛ-6, ИЛ-8 и ФНО-α и уменьшало концентрацию С-пептида в сыворотке, действуя на NF-kB-сигнальный путь. Включение метформина в комплексную терапию ИБС при МС препятствует активации NF-kB под действием эндогенных провоспалительных цитокинов.

The objective of the present study was to estimate the role of the NF-kB signal pathway in the realization of the anti-inflammatory and insulin-synthesizing activities of metformin in the patients presenting with coronary heart disease (CHD) associated with metabolic syndrome (MS). It was shown that the introduction of a one-month course of metformin therapy in the combined treatment of CHD resulted in the decreased production of pro-inflammatory cytokines, such as IL-1-beta, IL-6, IL-8, and TNF-alpha. Simultaneously, the serum C-peptide level decreased. These effects of metformin were mediated through the NF-kB-signal pathway. It is concluded that the inclusion of metformin in the combined treatment of coronary heart disease in the patients with metabolic syndrome prevent activation of NF-kB under the influence of endogeneous pro-inflammatory cytokines.

метформинишемическая болезнь сердцаметаболический синдроминсулинорезистентностьNF-kB-сигнальные путиmetformincoronary heart diseasemetabolic syndromeinsulin resistanceF-kB-signal pathwayReferencesDe Fronzo R.A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.De Fronzo R.A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.De Fronzo R.A. Insulin resistase, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010; 53: 1270-1287.De Fronzo R.A. Insulin resistase, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010; 53: 1270-1287.Bulcao C., Ribeiro-Filho F.F., Sanudo A. Roberta Ferreira S.G. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007; 7: 3: 219-224.Bulcao C., Ribeiro-Filho F.F., Sanudo A. Roberta Ferreira S.G. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007; 7: 3: 219-224.Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus. Prevocational report of WHO consultation. Diabet Med 1998; 15: 539-553.Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus. Prevocational report of WHO consultation. Diabet Med 1998; 15: 539-553.Juan M., Ohishi M., Wang L. et al. Association between serum levels of soluble CD40/CD40L ligand and organ damage in hypertensive patients. Clin Exp Pharmacol Physiol 2010; 37: 8: 848-851.Juan M., Ohishi M., Wang L. et al. Association between serum levels of soluble CD40/CD40L ligand and organ damage in hypertensive patients. Clin Exp Pharmacol Physiol 2010; 37: 8: 848-851.Lutgens E., Levens D., Beckers L. et al. CD40 and its ligand in aterosclerosis. Trends Cardiovasc Med 2007; 17: 4: 118-123.Lutgens E., Levens D., Beckers L. et al. CD40 and its ligand in aterosclerosis. Trends Cardiovasc Med 2007; 17: 4: 118-123.Lawrens T. The nuclear factor NF-kB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: 6: a001651.Lawrens T. The nuclear factor NF-kB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: 6: a001651.Hattori Y., Suzuki K., Hattori S., Kasal K. Metformin inhibits cytokine-induced nuclear factor kappa B activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006. 47: 6: 1183-1186.Hattori Y., Suzuki K., Hattori S., Kasal K. Metformin inhibits cytokine-induced nuclear factor kappa B activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006. 47: 6: 1183-1186.Huang N.L., Chiang S.H., Hsueh C.H. et al. Metformin inhibits TNF-alpha-induced I kappa B kinase phosphorylation, I kappa B alpha degradation and IL-6 production in ebdothelial cells through PI3-dependent AMPK phosphorylation. Int J Cardiol 2009; 134: 2: 169-175.Huang N.L., Chiang S.H., Hsueh C.H. et al. Metformin inhibits TNF-alpha-induced I kappa B kinase phosphorylation, I kappa B alpha degradation and IL-6 production in ebdothelial cells through PI3-dependent AMPK phosphorylation. Int J Cardiol 2009; 134: 2: 169-175.Wysocki P.J., Wizusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Exp Rev Mol Diagn 2010; 10: 4: 509-519.Wysocki P.J., Wizusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Exp Rev Mol Diagn 2010; 10: 4: 509-519.

The authors declare that there are no conflicts of interest present.